TY - JOUR AU - Mezőlaki, Noémi AU - Baltás, Eszter AU - Ócsai, Henriette AU - Varga, Anita AU - Korom, Irma AU - Varga, Erika AU - Németh, István Balázs AU - Kis, Erika AU - Varga, János AU - Kocsis, Ádám László AU - Gyulai, Rolland Péter AU - Bukva, Mátyás AU - Kemény, Lajos AU - Oláh, Judit Magdolna TI - Tumour regression predicts better response to interferon therapy in melanoma patients. a retrospective single centre study. TS - a retrospective single centre study. JF - MELANOMA RESEARCH J2 - MELANOMA RES VL - 34 PY - 2024 IS - 1 SP - 54 EP - 62 PG - 9 SN - 0960-8931 DO - 10.1097/CMR.0000000000000935 UR - https://m2.mtmt.hu/api/publication/34523817 ID - 34523817 AB - We hypothesise that regression may have an impact on the effectiveness of adjuvant IFN therapy, based on its role in the host immune response. Our purpose is to investigate regression and ulceration as prognostic factors in case of interferon-alpha (IFN)-treated melanoma patients. We followed 357 IFN-treated melanoma patients retrospectively, investigating progression-free survival (PFS) and overall survival (OS) depending on the presence of ulceration and regression. A Kaplan-Meier analysis was performed, and we used a Cox regression analysis to relate risk factors. The survival function of the Cox regression was used to measure the effect of regression and ulceration on PFS and OS depending on the Breslow thickness (T1-T4) of the primary tumour. Regression was significantly positively related to PFS ( P = 0.0018, HR = 0.352) and OS ( P = 0.0112, HR = 0.380), while ulceration showed a negative effect (PFS: P = 0.0001, HR = 2.629; OS: P = 0.0003, HR = 2.388). They influence survival independently. The most favourable outcome was measured in the regressed/non-ulcerated group, whereas the worse was in the non-regressed/ulcerated one. Of risk factors, Breslow thickness is the most significant predictor. The efficacy of regression is regardless of Breslow thickness, though the more favourable the impact of regression was in the thicker primary lesions. Our results indicate that regression is associated with a more favourable outcome for IFN-treated melanoma patients, whereas ulceration shows an inverse relation. Further studies are needed to analyse the survival benefit of regression in relation to innovative immune checkpoint inhibitors. LA - English DB - MTMT ER - TY - JOUR AU - Szűcs, Diána AU - Miklós, Vanda AU - Monostori, Tamás AU - Guba, Melinda AU - Kun-Varga, Anikó AU - Póliska, Szilárd AU - Kis, Erika AU - Bende, Balázs AU - Kemény, Lajos AU - Veréb, Zoltán TI - Effect of inflammatory microenvironment on the regenerative capacity of adipose-derived mesenchymal stem cells JF - IMMUNOLÓGIAI SZEMLE J2 - IMMUNOLÓGIAI SZEMLE VL - 15 PY - 2023 IS - 3 SP - 35 EP - 35 PG - 1 SN - 2061-0203 UR - https://m2.mtmt.hu/api/publication/34405844 ID - 34405844 N1 - HCEMM-SZTE Skin Research Group, University of Szeged LA - English DB - MTMT ER - TY - JOUR AU - Rózsa, Petra AU - Ágoston, Dóra AU - Szederkényi, Edit AU - Ócsai, Henriette AU - Baltás, Eszter AU - Vass, Gábor AU - Kemény, Lajos AU - Oláh, Judit Magdolna AU - Kis, Erika TI - Immunszupprimált betegek multiplex bőrdaganatainak elektrokemoterápiás kezelése [Electrochemotherapy for multiple cutaneous tumors in immunosuppressed patients] JF - ORVOSI HETILAP J2 - ORV HETIL VL - 164 PY - 2023 IS - 37 SP - 1462 EP - 1468 PG - 7 SN - 0030-6002 DO - 10.1556/650.2023.32852 UR - https://m2.mtmt.hu/api/publication/34340896 ID - 34340896 AB - Introduction: The risk of cutaneous malignancies is significantly higher in immunosuppressed patients compared to the general population. These high-risk skin tumors tend to be aggressive, multiplex, rapidly growing lesions. It is common to see local recurrence after surgical excision. Multiplex tumors are difficult to treat, especially in the head/ neck region.Objective: Amongst the standard treatment options, electrochemotherapy can be a suitable option. Our aim was to evaluate the efficacy of electrochemotherapy in immunocompromised patients.Method: In 9 immunosuppressed patients, 118 (average: 13, n = 5-27) non-melanoma skin tumors were treated with electrochemotherapy with intravenous administration of bleomycin, according to the ESOPE criteria.Results: The median follow-up was 15 months. 6 months after the treatment, the objective response rate was 96%. We observed complete response in 88%, partial response in 8% and progressive disease in 2% of the treated lesions. In 2%, the response was not evaluable.Conclusion: In immunocompromised patients, electrochemotherapy is an effective and safe therapeutic option for non-melanoma skin tumors. In order to provide more ideal management for this special sub-group, prevention, multidisciplinary approach and optimized immunosuppressive therapy is essential. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Di, Prata C AU - Mascherini, M AU - Ross, AM AU - Silvestri, B AU - Kis, Erika AU - Odili, J AU - Fabrizio, T AU - Jones, RP AU - Kunte, C AU - Orlando, A AU - Clover, J AU - Kumar, S AU - Russano, F AU - Matteucci, P AU - Muir, T AU - de, Terlizzi F AU - Gehl, J AU - Grischke, EM TI - Efficacy of Electrochemotherapy in Breast Cancer Patients of Different Receptor Status: The INSPECT Experience JF - CANCERS J2 - CANCERS VL - 15 PY - 2023 IS - 12 PG - 12 SN - 2072-6694 DO - 10.3390/cancers15123116 UR - https://m2.mtmt.hu/api/publication/34160965 ID - 34160965 LA - English DB - MTMT ER - TY - JOUR AU - Szűcs, Diána AU - Miklós, Vanda AU - Monostori, Tamás AU - Guba, Melinda AU - Kun-Varga, Anikó AU - Póliska, Szilárd AU - Kis, Erika AU - Bende, Balázs AU - Kemény, Lajos AU - Veréb, Zoltán TI - Effect of Inflammatory Microenvironment on the Regenerative Capacity of Adipose-Derived Mesenchymal Stem Cells JF - CELLS J2 - CELLS-BASEL VL - 12 PY - 2023 IS - 15 PG - 19 SN - 2073-4409 DO - 10.3390/cells12151966 UR - https://m2.mtmt.hu/api/publication/34085618 ID - 34085618 N1 - HCEMM-USZ Skin Research Group, University of Szeged, Hungary, TKP2021-EGA-28 AB - Adipose-derived mesenchymal stem cells are increasingly being used in regenerative medicine as cell therapy targets, including in the treatment of burns and ulcers. The regenerative potential of AD-MSCs and some of their immunological properties are known from in vitro studies; however, in clinical applications, cells are used in non-ideal conditions and can behave differently in inflammatory environments, affecting the efficacy and outcome of therapy. Our aim was to investigate and map the pathways that the inflammatory microenvironment can induce in these cells. High-throughput gene expression assays were performed on AD-MSCs activated with LPS and TNFα. Analysis of RNA-Seq data showed that control, LPS-treated and TNFα-treated samples exhibited distinct gene expression patterns. LPS treatment increased the expression of 926 genes and decreased the expression of 770 genes involved in cell division, DNA repair, the cell cycle, and several metabolic processes. TNFα treatment increased the expression of 174 genes and decreased the expression of 383 genes, which are related to cell division, the immune response, cell proliferation, and differentiation. We also map the biological pathways by further investigating the most altered genes using the Gene Ontology and KEGG databases. Secreted cytokines, which are important in the immunological response, were also examined at the protein level, and a functional assay was performed to assess wound healing. Activated AD-MSC increased the secretion of IL-6, IL-8 and CXCL-10, and also the closure of wounds. AD-MSCs presented accelerated wound healing under inflammation conditions, suggesting that we could use this cell in clinical application. LA - English DB - MTMT ER - TY - JOUR AU - Muir, Tobian AU - Bertino, Giulia AU - Groselj, Ales AU - Ratnam, Lakshmi AU - Kis, Erika AU - Odili, Joy AU - McCafferty, Ian AU - Wohlgemuth, Walter A AU - Cemazar, Maja AU - Krt, Aljosa AU - Bosnjak, Masa AU - Zanasi, Alessandro AU - Battista, Michela AU - de Terlizzi, Francesca AU - Campana, Luca G AU - Sersa, Gregor TI - Bleomycin electrosclerotherapy (BEST) for the treatment of vascular malformations. An International Network for Sharing Practices on Electrochemotherapy (InspECT) study group report JF - RADIOLOGY AND ONCOLOGY J2 - RADIOL ONCOL VL - 57 PY - 2023 IS - 2 SP - 141 EP - 149 PG - 9 SN - 1318-2099 DO - 10.2478/raon-2023-0029 UR - https://m2.mtmt.hu/api/publication/34043904 ID - 34043904 LA - English DB - MTMT ER - TY - JOUR AU - Varga, Ákos AU - Bende, Balázs AU - Baltás, Eszter AU - Németh, István Balázs AU - Varga, Erika AU - Vass, Gábor AU - Kis, Erika AU - Oláh, Judit Magdolna AU - Varga, János AU - Kocsis, Ádám László TI - Az SZTE Bőrgyógyászati és Allergológiai Klinikán a melanoma malignum sebészi kezelésében történt változások az elmúlt évtizedben [Changes in the surgical treatment of melanoma malignum at the Department of Dermatology and Allergology University of Szeged over the last decade] JF - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE J2 - BVSZ VL - 99 PY - 2023 IS - 2 SP - 122 EP - 124 PG - 3 SN - 0006-7768 DO - 10.7188/bvsz.2023.99.2.6 UR - https://m2.mtmt.hu/api/publication/33928935 ID - 33928935 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kis, Erika AU - Baltás, Eszter AU - Ócsai, Henriette AU - Csányi, Ildikó AU - Ottlakán, Aurél AU - Lázár, György ifj AU - Vass, Gábor AU - Ágoston, Dóra AU - Rózsa, Petra AU - Bottyán, Krisztina AU - Dalmády, Szandra AU - Nagy, András AU - Tóth-Molnár, Edit AU - Oláh, Judit Magdolna TI - Az elektrokemoterápia mérföldkövei [Milestones of electrochemotherapy] JF - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE J2 - BVSZ VL - 99 PY - 2023 IS - 2 SP - 116 EP - 120 PG - 5 SN - 0006-7768 DO - 10.7188/bvsz.2023.99.2.5 UR - https://m2.mtmt.hu/api/publication/33928735 ID - 33928735 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Campana, Luca G AU - Farronato, Sofia AU - Hodgetts, Jackie AU - Odili, Joy AU - Vecchiato, Antonella AU - Bracken, Alison AU - Baier, Susanne AU - Bechara, Falk G AU - Borgognoni, Lorenzo AU - Caracò, Corrado AU - Carvalhal, Sara AU - Covarelli, Piero AU - Clover, James AU - Eisendle, Klaus AU - Fantini, Fabrizio AU - Fierro, Maria Teresa AU - Farricha, Victor AU - Gregorelli, Chiara AU - Hafner, Jürg AU - Kunte, Christian AU - Gerlini, Gianni AU - Hessam, Schapoor AU - Mandalà, Mario AU - Piazzalunga, Dario AU - Quaglino, Pietro AU - Snoj, Marko AU - Ross, Alastair Mackenzie AU - Trigona, Béatrice AU - Moreno-Ramirez, David AU - Tauceri, Francesca AU - Peach, Howard AU - Rutkowski, Piotr AU - Muir, Tobian AU - de Terlizzi, Francesca AU - Patuzzo, Roberto AU - Mühlstädt, Michael AU - Dietrich, Karin-Almut AU - Mussack, Thomas AU - Matteucci, Paolo AU - Kis, Erika AU - Ascierto, Paolo AU - Sersa, Gregor AU - Valpione, Sara ED - Mauro, Alaibac / Collaborator ED - Paolo, Amerio / Collaborator ED - Paolo, Ascierto / Collaborator ED - Giuseppe, Azzarello / Collaborator ED - Susanne, Baier / Collaborator ED - Baltás, Eszter / Collaborator ED - Joana, Bartolo / Collaborator ED - Falk, Bechara / Collaborator ED - Francesco, Bellucci / Collaborator ED - Giulia, Bertino / Collaborator ED - Antonio, Bonadies / Collaborator ED - Lorenzo, Borgognoni / Collaborator ED - Mike, Bourke / Collaborator ED - Alison, Bracken / Collaborator ED - Paola, Brandani / Collaborator ED - Matteo, Brizio / Collaborator ED - Carlo, Cabula / Collaborator ED - Sarah, Calabrese / Collaborator ED - Luca, G Campana / Collaborator ED - Corrado, Caracò / Collaborator ED - Cinzia, Carriere / Collaborator ED - Sara, Carvalhal / Collaborator ED - Vanna, Chiarion / Collaborator ED - James, Clover / Collaborator ED - Piero, Covarelli / Collaborator ED - Pietro, Curatolo / Collaborator ED - Corrado, Dalio / Collaborator ED - Nicola, di Meo / Collaborator ED - Gianluca, Di Monta / Collaborator ED - Karin-A, Dietrich / Collaborator ED - Klaus, Eisendle / Collaborator ED - Tommaso, Fabrizio / Collaborator ED - Fabrizio, Fantini / Collaborator ED - Victor, Farricha / Collaborator ED - Virginia, Ferraresi / Collaborator ED - Francesco, Ferraù / Collaborator ED - Maria, T Fierro / Collaborator ED - Sara, Galuppo / Collaborator ED - Alessandro, Gatti / Collaborator ED - Julie, Gehl / Collaborator ED - Till, Geimer / Collaborator ED - Gianni, Gerlini / Collaborator ED - Chiara, Gregorelli / Collaborator ED - Ales, Groselj / Collaborator ED - Michele, Guida / Collaborator ED - Massimo, Guidoboni / Collaborator ED - Jürg, Hafner / Collaborator ED - Schapoor, Hessam / Collaborator ED - Jackie, Hodgetts / Collaborator ED - Jason, Kelly / Collaborator ED - Erika, Kis / Collaborator ED - Christian, Kunte / Collaborator ED - Alastair, McKenzie Ross / Collaborator ED - Giorgio, Manca / Collaborator ED - Mario, Mndalà / Collaborator ED - Ugo, Marone / Collaborator ED - Paolo, Matteucci / Collaborator ED - Andrea, Maurichi / Collaborator ED - Simone, Mocellin / Collaborator ED - David, Moreno-Ramirez / Collaborator ED - David, Mowatt / Collaborator ED - Michael, Mühlstädt / Collaborator ED - Tobias, Muir / Collaborator ED - Thomas, Mussack / Collaborator ED - Janja, Ocvirk / Collaborator ED - Joy, Odili / Collaborator ED - Judit, Oláh / Collaborator ED - Antonio, Orlando / Collaborator ED - Gaetano, Pascoletti / Collaborator ED - Roberto, Patuzzo / Collaborator ED - Howard, Peach / Collaborator ED - Dario, Piazzalunga / Collaborator ED - Camillo, Porta / Collaborator ED - Barry, Powell / Collaborator ED - Pietro, Quaglino / Collaborator ED - Simone, Ribero / Collaborator ED - Laura, Ridolfi / Collaborator ED - Rodrigo, Oom / Collaborator ED - Carlo, R Rossi / Collaborator ED - Ernesto, Rossi / Collaborator ED - Roberta, Rotunno / Collaborator ED - Piotr, Rutkowski / Collaborator ED - Giusy, Scandurra / Collaborator ED - Matteo, Sepulcri / Collaborator ED - Gregor, Sersa / Collaborator ED - Serena, Sestini / Collaborator ED - Marko, Snoj / Collaborator ED - Declan, Soden / Collaborator ED - Nicola, Solari / Collaborator ED - Pier, F Soma / Collaborator ED - Luca, Stingeni / Collaborator ED - Davide, Strippoli / Collaborator ED - Andrew, Sykes / Collaborator ED - Francesca, Tauceri / Collaborator ED - Alessandro, Testori / Collaborator ED - Bèatrice, Trigona / Collaborator ED - Angelo, Turoldo / Collaborator ED - Sara, Valpione / Collaborator ED - Antonella, Vecchiato / Collaborator ED - Marcin, Zdzienicki / Collaborator TI - European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma JF - BRITISH JOURNAL OF SURGERY J2 - BRIT J SURG VL - 110 PY - 2023 IS - 7 SP - 818 EP - 830 PG - 13 SN - 0007-1323 DO - 10.1093/bjs/znad105 UR - https://m2.mtmt.hu/api/publication/33928341 ID - 33928341 N1 - Dr. Baltás Eszter kollaborációs közreműködő LA - English DB - MTMT ER - TY - JOUR AU - Ottlakán, Aurél AU - Lázár, György ifj AU - Oláh, Judit Magdolna AU - Nagy, András AU - Vass, Gábor AU - Vas, Márton Árpád AU - Pereira, Raissa AU - Kis, Erika TI - Current Updates in Bleomycin-Based Electrochemotherapy for Deep-Seated Soft-Tissue Tumors JF - ELECTROCHEM J2 - ELECTROCHEM VL - 4 PY - 2023 IS - 2 SP - 282 EP - 290 PG - 9 SN - 2673-3293 DO - 10.3390/electrochem4020019 UR - https://m2.mtmt.hu/api/publication/33807738 ID - 33807738 AB - Electrochemotherapy (ECT) has evolved significantly during the last decade, expanding treatment indications from superficial skin lesions to advanced-stage, deep-seated tumors in hard-to-reach areas. Electrodes have also shown steady technological improvement throughout the years. Besides standard and VEG (variable geometry electrode) electrodes, the introduction of laparoscopic electrodes has brought on a new era in ECT treatment, making the minimally invasive approach a reality. The exact role of ECT in the oncological dashboard is yet to be determined; however, increased tumor response, pain relief, and a low number of adverse events may yield the way for more widespread application of the technique with possible further inclusion of ECT in international oncological guidelines. The aim of this review is to give an overview on the current status of ECT in deep-seated tumor treatment and shed light on its emerging role in local anticancer therapy. LA - English DB - MTMT ER -